Pharmaceutical composition for treating aplastic anemia

Abstract

The present invention relates to a pharmaceutical composition for treating aplastic anemia, which comprises Romiplostim as an active ingredient, wherein the pharmaceutical composition is administered subcutaneously once a week, wherein Romiplostim is administered at 10 μg/kg/week for 4 weeks from the start of administration, administered at more than 10 μg/kg/week and at a maximum of 20 μg/kg/week after week 5.

[Fig.1]